---
schema_version: "secwatch.filing_event.v1"
accession: "0001730463-24-000129"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:03:30.221906+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# FDA approves Autolus' AUCATZYL (obe-cel) for adult r/r B-ALL; no REMS required

## Summary
- Approval based on FELIX trial: 63% overall complete remission (CR/CRi) in efficacy-evaluable patients (n=65); median DOR 14.1 months.
- Only 3% Grade ≥3 CRS and 7% Grade ≥3 ICANS; no REMS program required by FDA.
- Boxed warning for CRS, neurologic toxicities, secondary hematological malignancies; T-cell malignancies risk noted.
- Commercial manufacturing at Nucleus in Stevenage, UK; Cardinal Health as U.S. distribution partner.
- EU and UK MAAs under review; company to host conference call Nov 11.

## SEC filing metadata
- accession: 0001730463-24-000129
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000129/0001730463-24-000129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000173046324000129/autl-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001730463-24-000129
- JSON: https://secwatch.observer/filing/0001730463-24-000129.json
- Plain text: https://secwatch.observer/filing/0001730463-24-000129.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.